EMA: AUC72 for all IR products [General Sta­tis­tics]

posted by pmohite – India, 2020-06-24 12:08 (298 d 11:24 ago) – Posting: # 21573
Views: 1,275

Hello,

The Revised EMA Bioequivalence Guideline, Questions & Answers, Summary of the discussions held at the 3rd EGA Symposium on Bioequivalence, June 2010, London, Session 3 under question 12 states as follows:

In studies with a sampling period of 72 h, and where the concentration at 72 h is quantifiable, AUC(0-∞) and residual area do not need to be reported; it is sufficient to report AUC truncated at 72h, AUC(0-72h). A mixture of AUCt and AUC72 is acceptable as long as the sampling period allows for an adequate characterisation of AUCt. Of course, in the event samples were absent because of protocol violations on a mass scale then this would affect the acceptability of the study.


If there are around 25% of subjects missed this interval, then this will raise the acceptance of study.

Regards.


Edit: Document linked. [Helmut]

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 13 (0 registered, 13 guests [including 3 identified bots]).
Forum time: Sunday 23:32 CEST (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5